SCHEDULE: Vanguard Group Reports Zero Stake in Rocket Pharma Post-Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Rocket Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to its Schedule 13G for Rocket Pharmaceuticals Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, effective January 12, 2026.
• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately, in reliance on SEC Release No. 34-39538.
• These subsidiaries and/or business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Rocket Pharmaceuticals Inc., as it primarily reflects an administrative reporting change by The Vanguard Group due to an internal realignment, rather than a change in investment thesis or a divestment based on Rocket Pharmaceuticals' performance.

Negatives

• The Vanguard Group, a prominent institutional investor, no longer reports beneficial ownership of Rocket Pharmaceuticals Inc. common stock, which could be misinterpreted as a divestment if the context of the internal realignment is not fully understood.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Rocket Pharmaceuticals Inc.'s future performance or operations.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that this filing primarily reflects an administrative change in reporting structure for The Vanguard Group, rather than a shift in investment strategy related to Rocket Pharmaceuticals Inc. or broader industry trends. Such internal realignments by large asset managers are not uncommon and typically aim to optimize compliance and operational efficiency.

Stakeholder Impact

• Shareholders of Rocket Pharmaceuticals Inc. should be aware that The Vanguard Group, Inc. as a single entity no longer reports beneficial ownership, though affiliated entities may still hold shares and report them separately. This could lead to a perceived reduction in institutional ownership if the context is not fully understood.

Key Dates

Keywords

Vanguard Group, Rocket Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Internal Realignment